Chuangyebang was informed that recently, Shanghai Aoquan Biomedical Technology Co., Ltd. (hereinafter referred to as “Aoquan Bio”) announced the completion of nearly 100 million yuan in Series B financing, led by Deyi Capital, followed by China Merchants Securities Investment, and the original shareholder Kaitai Capital, Zhangke Herun, and Qiaobei Capital continued to overweight. The funds raised this time will be mainly used for the construction of new production bases, the market promotion of innovative drug delivery platforms, and the research and development, clinical and production of pipelines under development.
Founded in 2019, Aoquan Bio is an international biopharmaceutical company dedicated to the R&D and industrialization of high-end improved formulations. Its R&D center in Pudong, Shanghai is responsible for R&D, production, and clinical and application of projects in China; it is located in the United States Auson Pharmaceuticals INC in New Jersey is responsible for product declaration, production and commercial promotion in the United States.
Aoquan makes targeted improvements to drugs based on the clinical needs of patients, and explores new treatment methods, including new dosage forms, new indications and new dosing regimens. FDA and China NMPA are also introduced into the market to meet the unmet clinical needs of domestic and foreign patients. The company focuses on the research and development and innovation of new drug formulations with independent intellectual property rights, focusing on the fields of pediatrics, vascular diseases and antiviral, with the ultimate goal of product marketization.
The founder of the company, Dr. Lu Enxian, holds a master’s degree in pharmacy from Fudan University, a master’s degree in biopharmaceuticals from the University of Illinois, and a doctorate in pharmacy from the University of Minnesota. He has more than 20 years of working experience in MNC pharmaceutical companies and start-up pharmaceutical companies. Served as R&D and management positions; co-founded Aucta in 2012 and served as the general manager, as the R&D leader to promote the development and approval of multiple products.
Aoquan’s R&D pipeline covers pediatrics, cardiovascular, antiviral and other therapeutic areas. The first product ASN001 for the treatment of infantile hemangiomas has completed Phase I clinical trials in China, and multi-center confirmatory clinical trials will be completed in 2022Q4. Signed a sales cooperation agreement with a well-known multinational pharmaceutical company; the cerebrovascular product ASN010 will be launched in China in 2022Q3; the new cardiovascular drug ASN006 will submit an NDA application to the US FDA in 2022Q4; at the same time, Aoquan has been committed to drug delivery without interruption The research on difficult solutions allows more groups with difficult drug administration to obtain solutions, and improves the accuracy, safety and convenience of drug use. The related patented products Leyipei and Yijiaan (for pets) have been marketed.
The founder of the company, Dr. Lu Enxian, said: Thank you for the trust of new and old investors, for their firm support in the development of Aoquan, and to witness the rapid growth of Aoquan together. This round of financing will greatly help the company expand its scale and develop and market more innovative products. Aoquan will continue to seek and discover unmet clinical needs, and use its own experience and advantages to comprehensively help improve the industrialization of new drugs and improve the quality of people’s healthy life.
Zhang Li, executive director of Deyi Capital, said: We are optimistic about the differentiated topic selection ideas of Lu Bo and the company’s team, the efficient R&D promotion, and the ability to continuously tap new market demands. These capabilities are built on the management team’s years of drug development, working experience in multinational pharmaceutical companies, and a solid foundation in successful pharmaceuticals. We look forward to continuing to work together with the team and new and existing shareholders to support the rapid development of Aoquan to meet the unmet clinical needs at home and abroad.
attached
For more project information, please go to ” Analysis of Rui Beast “.
media coverage
Yiou Venture Capital Investment Circle
Related events
- “Aoquan Bio” completed nearly 100 million yuan in Series B financing, led by Deyi Capital2022-08-05
- Zhenge Bio raised $70 million in Series B financing2021-03-22
- “Highgrade Bio” completed a $67 million Series C financing led by IDG Capital2019-08-28
- Cosmetics group Xiaoya Bio completed tens of millions of A+ rounds of financing2019-07-02
This article is reprinted from: https://readhub.cn/topic/8ieeaKCkS5d
This site is for inclusion only, and the copyright belongs to the original author.